Retatrutide: Weight Loss, Dosing, Side Effects 2026

Q: Is retatrutide a GLP-3 drug?

No. GLP-3 is an inaccurate internet nickname. Retatrutide activates GIP, GLP-1, and glucagon receptors.

Q: How much weight did people lose with retatrutide?

The 12 mg group in TRIUMPH-1 lost an average of 28.3% at 80 weeks. Participants with a starting BMI of at least 35 who entered the extension reached 30.3% average weight loss at 104 weeks.

Q: Does retatrutide preserve muscle?

Retatrutide reduces fat mass and lean mass. Current DXA evidence suggests the proportion of lean-mass loss is similar to other major obesity interventions rather than disproportionately high.

Q: Does TRT prevent muscle loss from retatrutide?

No clinical trial has demonstrated that TRT prevents retatrutide-associated lean-mass loss.

Q: Is retatrutide better than tirzepatide or semaglutide?

No Phase 3 head-to-head obesity trial has established superiority over tirzepatide or semaglutide. Separate trials differ in study populations, duration, diabetes status, adherence, discontinuation rates, lifestyle programs, and statistical methods. Cross-trial percentages do not provide a clean head-to-head comparison.

Q: What retatrutide doses were studied?

The Phase 3 obesity program studied maintenance targets of 4 mg, 9 mg, and 12 mg. Participants generally began at 2 mg weekly and escalated every four weeks according to the trial protocol.

Q: Is the Phase 3 dosing schedule an approved retatrutide protocol?

No. These doses describe clinical research protocols. Retatrutide has no FDA-approved dosing instructions.

Q: Is compounded retatrutide legal in the United States?

FDA states that retatrutide is not eligible for compounding under federal law.

Q: When is retatrutide expected to reach the FDA?

Lilly plans to submit retatrutide for U.S. regulatory review in the first quarter of 2027. No approval date or commercial launch date has been confirmed.

KizzaP96 · May 10, 2025

I've decided to source some retatrutide from a Chinese supplier via platforms like Made-in-China or Alibaba, and I’m planning to order 10 x 10mg vials strictly for personal use. I'm currently on 10mg trizepitide from eli lilly and have been doing extensive research around it.

My plan is to send one vial to Janoshik for testing, provided all vials are from the same batch. Assuming the quality checks out, I intend to follow this dosing protocol:

Week 1: 0.25mg twice per week
Week 2: 0.25mg twice per week
Week 3: 0.50mg twice per week
Week 4: 0.50mg twice per week
Week 5: 0.50mg twice per week
Week 6: 0.50mg twice per week
...and so on.

From what I’ve read, a reconstituted 10mg vial only remains stable for about 28–35 days when refrigerated. Based on available information, it seems you can pre-load insulin syringes and freeze them — then thaw them in the fridge a day before use — but opinions are mixed.

Given that I’m relatively new to this, here are the concerns I currently have:

Is Janoshik the most reliable peptide testing service in the EU, and what is their typical turnaround time?
Is it safe to freeze retatrutide in preloaded insulin syringes? Some peptides degrade when frozen — does this apply to retatrutide?
How can I ensure sterile technique? I want to avoid contamination during reconstitution and dosing.
How do I verify the accuracy of micro-doses in insulin syringes? With such small doses, slight errors can matter.
What signs of degradation should I watch for in reconstituted or frozen peptides?
How should I store unopened lyophilized vials? Is room temperature okay, or should they be kept refrigerated?

brookseth · May 10, 2025

1. Yes Janoshik is reliable. about 2-4 weeks after receiving your products.
2. No, you should not freeze reconstituted peptides as this can cause degredation.
3. You use an alcohol swab on the vial and injection site, also use clean / fresh needles and syringes
4. not sure what you are asking here, you need to just make sure you draw to the correct number of units.
5. vial should just be clear liquid without and foreign substances. that being said you could have degradation or endotoxins not visible to the eye.
6. refrigerator or frozen for lyophilized vials.

Also - your dosing protocol is WAY off for retatrutide. dosing is similar to tirzepatide.

I mean this very respectfully when I say this, but you have mentioned that you "have been doing extensive research" and to be honest this post tells me otherwise.
I would strongly recommend researching further and making sure you have a more well rounded knowledge of what you are doing before self prescribing, ordering from china, and self injecting any compounds.

Vince · May 10, 2025

Sounds like an awesome drug. If retatrutide makes through trials.

If they ever make these drugs cost efficient, there never will be anyone fat again.

FunkOdyssey · May 10, 2025

Vince said:
Sounds like an awesome drug. If retatrutide makes through trials.

If they ever make these drugs cost efficient, there never will be anyone fat again.

This doesn't seem entirely true. Without lifestyle changes, dose escalation is required over time to maintain the effects, until eventually tolerance builds to the highest tolerable dose and weight starts increasing again even as the drug is continued. This process seems to take a few years from what I've heard, but it doesn't appear to be a life-long solution.

KizzaP96 · May 11, 2025

brookseth said:
1. Yes Janoshik is reliable. about 2-4 weeks after receiving your products.
2. No, you should not freeze reconstituted peptides as this can cause degredation.
3. You use an alcohol swab on the vial and injection site, also use clean / fresh needles and syringes
4. not sure what you are asking here, you need to just make sure you draw to the correct number of units.
5. vial should just be clear liquid without and foreign substances. that being said you could have degradation or endotoxins not visible to the eye.
6. refrigerator or frozen for lyophilized vials.

Also - your dosing protocol is WAY off for retatrutide. dosing is similar to tirzepatide.

I mean this very respectfully when I say this, but you have mentioned that you "have been doing extensive research" and to be honest this post tells me otherwise.
I would strongly recommend researching further and making sure you have a more well rounded knowledge of what you are doing before self prescribing, ordering from china, and self injecting any compounds.

I've spent 3 weeks researching it,

I've seen everywhere from starting at 2mg a week to .25mg a week, read the Eli lilly trial results also, but of course there is so much mixed information out there I don't know who to trust.

The company that's testing it in trials or the people who've actually been taking it for months.

Fucking AI added that 4th question in when I asked it to polish up what I wanted, it added like 6 silly questions but I must have missed that one.

KizzaP96 · May 11, 2025

FunkOdyssey said:
This doesn't seem entirely true. Without lifestyle changes, dose escalation is required over time to maintain the effects, until eventually tolerance builds to the highest tolerable dose and weight starts increasing again even as the drug is continued. This process seems to take a few years from what I've heard, but it doesn't appear to be a life-long solution.

That's why you use it as a tool, similar to those who are diabetic in insulin.

Ive been on a pretty strict diet since the start of trizeptide I lost like 60lbs however I have stalled in recent weeks because I've been so sick I've not left my bed really, but once I get a diagnosis from hospital and get some medication in me to fix what ever the f is up I will be straight back in the gym but at the moment I wake up with no feeling in my legs and feeling like complete ass.

Vince · Nov 21, 2025

BadassBlues said:
I have not had very good experiences with GLP-1 drugs. The appetite suppression was nice, but the gastrointestinal side effects were a deal breaker. Semaglutide and Tirzepatide both shut down my digestive system. My wife has been on Retatrutide for a few months with very good results. I need to lose some stubborn belly fat, so I decided to give it a try. After 2 weeks of use, I have lost 8 pounds and have zero side effects. Retatrutide is not yet FDA approved but has gone through clinical trials and has so far been deemed safe and effective. This drug is a GLP-1, GIP and Glucagon Receptor activator.

So far so good... we'll see how it goes.

Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMC

Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide ...

pmc.ncbi.nlm.nih.gov

Retatrutide—A Game Changer in Obesity Pharmacotherapy
Vasiliki Katsi 1,*, Georgios Koutsopoulos 1, Christos Fragoulis 1, Kyriakos Dimitriadis 1, Konstantinos Tsioufis 1
Editors: Othmar Moser1, Harald Sourij1

Author information

Article notes

Copyright and License information

PMCID: PMC12190491 PMID: 40563436

Abstract
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide’s mechanisms, efficacy, and safety profile. Retatrutide’s unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide’s ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide’s long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.
Keywords: retatrutide, obesity, incretins, type 2 diabetes mellitus

1. Introduction
Obesity has emerged as a pressing global health crisis, often referred to as a pandemic due to its widespread prevalence and significant impact on public health. It is estimated to be responsible for approximately 3.4 million deaths each year worldwide, underscoring its severity as a major contributor to mortality rates [1]. Clinically, it is characterized by an excess accumulation of adipose tissue within the body, and it is formally defined as a body mass index (BMI) of ≥30 kg/m2. It can affect patients both on a psychological and physical level, with overweight and obese people found to be at risk for diabetes, cardiovascular disease, cancer, and premature death [2]. This has a significant toll on life expectancy, which is shown to be reduced by 7 years at the age of 40 years [3]. Added to that, it is constantly growing in scale with an estimated projection of overweight and obese adults at 1.35 billion and 573 million, respectively, by the year 2030 [4].
Coming hand in hand with obesity, type 2 diabetes mellitus (T2DM) poses a considerable threat to individual health and a significant burden on the world’s financial health policy. Described as a disorder of glucose homeostasis and insulin sensitivity, it is primarily triggered by uncontrolled hyperglycemia, and it is responsible for a large number of microvascular (like diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy) and macrovascular complications (like diabetic foot syndrome, cerebrovascular events, and myocardial infarction) [5]. The presence of T2DM also increases susceptibility to a variety of cancers (such as liver, biliary tract, pancreas, stomach, colorectal, kidney, bladder, breast, and endometrial) and infections (like respiratory, urinary tract, and skin and soft tissue infections) [6].
A tight interplay between these two is a common finding in many patients, and many metabolic pathways show their close pathophysiological connection. For example, the global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) among diabetic patients is estimated at 65.33% and 66.44%, respectively [7].
Unhealthy diets and sedentary lifestyles are pivotal predisposing factors contributing to the growing global burden of obesity, T2DM, and metabolic dysfunction-associated fatty liver disease (MAFLD). Diets rich in saturated fats, refined carbohydrates, and ultra-processed foods—hallmarks of the Western dietary pattern—have been consistently linked to excessive adiposity, insulin resistance, and chronic systemic inflammation [8]. These conditions are central to the pathogenesis of both T2DM and MAFLD, forming a critical component of the broader metabolic syndrome. Additionally, prolonged physical inactivity further compounds these risks by diminishing metabolic flexibility and impairing insulin sensitivity, independent of body weight [9]. The synergistic effect of poor dietary quality and lack of exercise creates a fertile ground for the development and progression of metabolic disorders.
Intervention through lifestyle modification remains the first-line therapeutic strategy. Notably, adherence to the Mediterranean diet—a dietary pattern rich in fruits, vegetables, whole grains, olive oil, and lean proteins—has demonstrated significant improvements in hepatic steatosis and insulin resistance among patients with MAFLD [10]. Furthermore, structured exercise regimens incorporating both aerobic and resistance training have been shown to reduce liver fat content and improve glycemic control [11]. However, despite the well-documented benefits of lifestyle changes, maintaining long-term adherence remains a challenge for many individuals, often requiring multidisciplinary support and long-term behaviour change strategies. When necessary, pharmacological interventions are essential to eliminate the gap for effective prevention and management of these interrelated conditions.
Numerous pharmacological treatments seek to disrupt these harmful connections, with a considerable number focusing on the incretin hormonal pathways and appetite regulation. Three of the most common incretin peptide hormones are Glucagon-Like Peptide (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and Glucagon. The emergence of GLP-1 receptor agonists, such as the first clinically approved agonist, exenatide, in 2005, paved the way for the thorough exploration of these molecules [12]. Shortly, other molecules such as liraglutide, dulaglutide, and semaglutide came forth, offering a once-weekly dosage. Beyond achieving more effective glucose control and offering worthy weight loss, these medications achieved a reduction in rates of major adverse cardiovascular effects, heart failure, kidney disease, and cardiovascular death [13,14,15]. These promising results led to the development of the first dual agonists, with tirzepatide, a GIP and GLP-1 receptor agonist, being the most prominent one. Tirzepatide achieved significant reductions in Glycated Hemoglobin A1c (HbA1c) levels and body weight compared to placebo. Additionally, tirzepatide was found to have a more pronounced effect compared with the GLP-1 agonist semaglutide in people with T2DM. The incidence of gastrointestinal (GI) adverse events was increased compared with placebo; however, neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia [16].
A first-of-its-class triple receptor agonist, retatrutide, aims to deliver a revolution in obesity and T2DM pharmacotherapy. This groundbreaking medication is shown to enhance therapeutic outcomes by delivering more pronounced reductions in both body weight and HbA1c levels than current pharmacotherapies.

2. Materials and Methods
A review of the literature was conducted to examine the potential impact of the emerging drug retatrutide on T2DM and obesity pharmacotherapy. The search was carried out on Medline using the keywords: retatrutide, T2DM, obesity, and novel pharmacotherapy, in combination with the boolean operators AND or OR. Only articles published in English from 2005 onwards were included, with the most recent search conducted in April 2025.

3. Targeted Molecules
3.1. Glucagon-like Peptide (GLP-1)
GLP-1 is an incretin hormone that is predominantly secreted from the intestinal tract, mainly as a response to meals. Small Intestine L-cells are responsible for their production from a proglucagon gene [17]. Production of this molecule is also shown to occur in pancreatic α-cells and the central nervous system in areas like the nucleus tractus solitarius and microglia [18]. It predominantly acts by activating a receptor that induces stimulation of insulin release, decreases glucagon secretion, reduces food intake, and delays gastric emptying (GE) by affecting gastric and intestinal motility [19]. GLP-1 receptors can be found in a variety of tissues such as the pancreas, gastric mucosa, kidney, lung, heart, skin, immune cells, and brain. They are 463 amino acid heptahelical G protein-coupled receptors that, when activated, stimulate cyclic adenosine monophosphate (cAMP) formation followed by activation of protein kinase A pathways [20].
Especially regarding the central nervous system, the expression of GLP-1 receptors in reward-related regions, such as the hypothalamus, amygdala, nucleus accumbens, paraventricular nucleus, ventral tegmental area, locus coeruleus, and brain stem [21] may suggest a possible association between reward learning and symptoms like anhedonia in diseases such as depression. However, the multifactorial and polygenic nature of this diagnosis requires further investigation before establishing a rigid conclusion [22]. GLP-1 activation is also shown to reduce inflammation by reducing macrophage activity [23]. Its effects on satiety and food intake are found in healthy individuals as well as in obese and diabetic patients [24].

3.2. Glucose-Dependent Insulinotropic Polypeptide (GIP)
Also excreted from intestinal K cells, GIP is a protein mostly postprandially secreted [25]. It consists of 42 amino acids that take form after proteolysis of a 153-amino acid precursor. GIP receptors exist as two isoforms, consisting of 466 and 493 amino acids, respectively, that, when activated, display an increase in intracellular calcium and arachidonic acid. Their activation is also related to adenylyl cyclase activation. By acting on these receptors that are expressed in multiple tissues, including primarily pancreatic β-cells and secondarily adipose and nervous tissue, GIP stimulates glycogen secretion both in normoglycemic and hyperglycemic states. It also reduces appetite by having a negative impact on GE and by enabling insulin release from the pancreas, acting in tandem with GLP-1 [26]. However, it acts in contrast with GLP-1 as much as glucagon release is concerned by enhancing its release. Furthermore, growth factor-dependent pathways such as MAPK (extracellular signal-regulated kinases 1 and 2 [ERK 1/2]) and protein kinase B are found to be affected by GIP activation [20]. GIP effects regarding adipose tissue are also described as it is shown to stimulate adipogenesis, inhibit lipolysis, and stimulate de novo lipogenesis [27]. Additionally, GIP is shown to have a direct influence on bone, inducing osteoblast activity [28].

3.3. Glucagon
Finally, glucagon, formed from a precursor pro-glucagon molecule of 180 amino acids, is a hormone that is mostly found in pancreatic α-cells [19]. Production in the small intestine is also described [28]. After its discovery in 1921, its contribution to the pathophysiology of type 2 diabetes mellitus opened a new age in antidiabetic medications and in the study of metabolic diseases. It consists of 29 amino acids [29] and its gene is located on chromosome 2 [30]. Glucagon receptors are mainly found in the liver hepatocytes and in the kidneys. Less expression is also described in other tissues such as the heart, pancreas, adipose tissue, and the GI tract. Glucagon receptors are G protein-coupled receptors that, when stimulated, lead to an increase in intracellular cAMP and calcium that, in advance, activate the protein kinase A pathway [31,32]. Its main drive of release is low glucose blood levels, and glucagon receptors are found in many tissues, with hepatocytes being the most common place. Glucagon allows gluconeogenesis and glycogenolysis in the liver while blocking glycogenesis. These effects lead to high blood glucose levels. Glucagon also reduces GI motility [33] and, by acting on adipose tissue, decreases lipogenesis and induces lipolysis, leading to increased production of non-esterified fatty acids and ketone bodies. Glucagon is also found to affect brown fat in animal models, inducing thermogenesis and energy expenditure. However, human experiments have not proven more than a modest effect on energy expenditure, not achieving clinical significance [28].

4. General Aspects of Retatrutide
Molecular Structure—Pharmacology
A promising new therapy that targets all the previously mentioned molecules is the triple receptor agonist retatrutide. Retatrutide is a synthetic peptide acting as an agonist of GLP-1, GIP, and glucagon receptors (Figure 1). Retatrutide’s engineering allows it to bind uniquely to these receptors [34].

Figure 1.

Open in a new tab
Retatrutide’s mechanisms of action.
Retatrutide develops in a single continuous helical structure that allows it to run through the receptor’s transmembrane domain with its N-terminal segment. The C-terminal segment takes part in interactions with the N-terminal α-helix of the extracellular domain, the extracellular tip of the transmembrane helix 1 of the GLP-1 receptor, and the extracellular loop 1 of the GIP receptor. This molecule is more potent at the human GIP receptor (EC50: 0.0643 nM) and less potent at the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors [35]. It has a dose-dependent action and causes a decrease in gastric emptying, while with a half-life of 6 days, it can mostly be used on a weekly basis. Retatrutide shows mostly hepatic metabolism but does not interact with cytochrome P450 enzymes [36].
Its effects lead to significant weight reduction and to a decrease in HbA1c levels [37]. The most commonly occurring adverse effects are nausea, diarrhea, vomiting, and constipation. However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages. Practical studies indicate that the discontinuation rates of GLP-1RAs can reach between 20% and 50% within the first year, and patients often use significantly lower dosages compared to those tested in clinical trials [38]. Less common adverse effects were a temporary increase in alanine aminotransferase (ALT) levels, increased heart rate, and skin hyperesthesia [39].

5. Insights from Animal Studies
In recent years, retatrutide has amassed a respectable number of animal and clinical studies (Table 1).

Table 1.
Concise summary of key retatrutide studies.

[th]
Type of Study

[/th][th]
Year

[/th][th]
Studies

[/th]
[td]
Animal Study (mice)

[/td][td]
2017

[/td][td]
Jall et al.

[/td]
[td]
Animal Study (mice)

[/td][td]
2023

[/td][td]
Urva et al.

[/td]
[td]
Animal Study (mice)

[/td][td]
2024

[/td][td]
Ma et al.

[/td]
[td]
Phase I Clinical Study

[/td][td]
2022

[/td][td]
Coskun et al.

[/td]
[td]
Phase I Clinical Study

[/td][td]
2022

[/td][td]
Urva et al.

[/td]
[td]
Phase II Clinical Study

[/td][td]
2023

[/td][td]
Jastreboff et al.

[/td]
[td]
Phase II Clinical Study

[/td][td]
2023

[/td][td]
Rosenstock et al.

[/td]
[td]
Phase II Clinical Study

[/td][td]
2024

[/td][td]
Sanyal et al.

[/td]

Open in a new tab
With delayed GE being an important effect of weight-lowering drugs acting on glucagon, Urva et al. attempted to investigate retatrutide’s effect, compared with other selective GLP-1 receptor antagonists on animal models [40]. C57/B16 male obese mice (Jackson) were singly housed and maintained on a standardized diet (TD95217; Teklad) with ad libitum water; 16 h before the assessment of acute GE, mice were fasted overnight and treated subcutaneously with either vehicle (10 mL/kg; 40 mM Tris pH 8), long-acting glucagon receptor agonist, semaglutide, retatrutide, or combined semaglutide and long-acting glucagon receptor agonist. Mice were administered 0.5 mL of semi-liquid by oral gavage, and GE was subsequently assessed. GE delay, body weight, and food intake were also assessed following chronic (daily for 10 days) treatment with vehicle, semaglutide, long-acting glucagon receptor agonist, retatrutide, or combined semaglutide and long-acting glucagon receptor agonist. Retatrutide achieved delayed GE in mice in a dose-dependent fashion, as well as semaglutide. The dual combination of them did not manage to differ statistically from the usage of retatrutide alone. 10 nmol/kg of retatrutide achieved a bigger weight drop over 10 days than the other combinations. Furthermore, retatrutide showed the largest decreases in food intake, and chronic treatment for 10 days attenuated the described effects. However, there are some limitations to the study. The method used in the study is not the gold standard scintigraphy that involves radioactive tracers, and the researchers did not take into account secretion-based error [40].
Another study by Ma et al. aimed to compare the effects of retatrutide, liraglutide, and tirzepatide on diabetic kidney disease in db/db mice [41]. The seven-week-old male C57BL/KSJ diabetic db/db and db/m mice were housed in an ambient temperature of 21 ± 2 °C and humidity of 45 ± 10%, maintained under a 12 h light/dark cycle. At 8 weeks of age, the mice were randomly divided into 5 groups (each n = 6): db/m, db/db, db/db + Lira, db/db + Tirz, and db/db + Reta. Each treatment group was divided into two cages with three mice in each cage. The mice in db/db + Lira, db/db + Tirz, and db/db + Reta groups received daily subcutaneous injections of 10 nmol/kg of liraglutide, tirzepatide, and retatrutide for 10 weeks, respectively. The db/m and db/db groups were given an equal amount of saline intraperitoneally over the same time. The dose of the drug was adjusted weekly throughout the study period based on changes in the weight of the mice. Weekly, a glucometer was used to assess the fasting blood glucose (FBG) levels. HbA1c values were measured at the beginning and end of the experiment. After a duration of 10 weeks, urine samples were collected from individually housed mice in metabolic cages over a 24 h period, followed by recording of urine volumes and storage at −80 °C for further analysis. Subsequently, the mice were anesthetized, and blood samples were obtained from the intraorbital venous plexus. After the completion of the experiment, a histopathological analysis was performed, followed by immunohistochemical staining. At the end of the experiment, the weight of mice in the db/db + Reta group decreased, and at 10 weeks, db/db + Reta group mice had the lowest levels of body weight and food intake, followed by db/db + Tirz group and db/db + Lira group, with a statistically significant difference. These findings strongly indicate that all three drugs are effective in reducing food intake and promoting weight loss, with retatrutide demonstrating the most significant impact. Regarding HbA1c levels, retatrutide showed lower levels than those in the db/db group. In addition, the db/db + Reta group demonstrated superior efficacy in reducing alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, and low-density lipoprotein levels. Finally, after immunohistochemical analysis, retatrutide exhibited lower expression levels of inflammatory and fibrotic mediators compared to tirzepatide and liraglutide, highlighting its potential in the treatment of diabetic kidney disease.
Last but not least, Jall et al. showed a reversal of steatohepatitis in female mice by resulting in enhanced glucose tolerance, decreased body weight and fat mass, and better lipid profiles, thereby aiding in the resolution of hepatic steatosis [42]. Both female and male C57BL/6J mice at an eight-week age received a diet rich in fat and sugar. Due to differences in obesity progression between the two sexes, another cohort of male C57BL/6J mice was switched from a regular diet to a high-fat, high-sugar diet at 30 weeks of age. The mice were maintained at a temperature of 23 ± 1 °C, constant humidity, and on a 12 h light-dark cycle. After 38 weeks of age, mice were randomized within the three cohorts and equally distributed according to body composition. Mice were subcutaneously injected with the triple agonist and immediately followed by fasting for a 4 h period. Afterwards, formalin-fixed liver samples were collected. Histological analysis showed that up to 88.9% and 62.5% of female and male vehicle-treated mice, respectively, were diagnosed with definite steatohepatitis. The administration of the triple agonist resulted in the improvement of steatohepatitis in a dose-dependent fashion, with some female mice showing a complete resolution.

6. Insights from Human Studies
6.1. Phase I Trials
Coksun et al. in Singapore conducted a phase 1 study to assess the safety and the pharmacokinetic profile of retatrutide [35]. 47 healthy individuals entered the study, while 45 of them received at least one dose. Maximum concentration was achieved within 12–72 h after dosing. The mean half-life was about 6 days. When compared with placebo, retatrutide achieved similar changes in baseline fasting glucose levels. After dosing at 4.5 and 6 mg, mean fasting glucagon levels were decreased from 24 h post-dose up to day 15. Retatrutide achieved a decrease in mean body weight at all dose levels except at the dose of 0.1 mg. The decrease in weight was at its peak at dose levels of 3–6 mg. The most common study treatment-related adverse effects were GI disorders such as vomiting, abdominal distention, and nausea, however, mostly of mild intensity.
Following their animal studies, Urva et al. designed a phase 1b, multiple-ascending dose study in type 2 diabetic patients [40]. These patients received retatrutide once weekly (in dosage groups of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg), placebo, or 1.5 mg of dulaglutide. Retatrutide 0.5, 1.5, and 3 mg were administered for 12 weeks. The 3/6 mg group received 3 mg of retatrutide for weeks 1–4 and 6 mg for weeks 5–12. Finally, the 3/6/9/12 mg group received 3 mg for the first two weeks, 6 mg for weeks 3–4, 9 mg for weeks 5–8, and 12 mg for weeks 9–12. Gastric emptying was assessed 2 days pre-treatment and 24 h after the dose at day 2, day 30, and day 79. In summary, 72 of the participants received at least 1 dose of the drug, while 43 completed the study. The mean study age was 58.4 ± 7.4 years, mean ΒΜΙ was 32.1 ± 5.1 kg/m2, HbA1c 8.66 ± 0.92% [43]. The greatest effect on GE was found after the first retatrutide dose, while it was lower on subsequent doses, despite up-titration.

6.2. Phase II Trials
In a phase II double-blind, randomized, placebo-controlled trial, Jastreboff et al. administered retatrutide in doses up to 8 mg for a total of 48 weeks in patients with a BMI ≥ 30 kg/m2 or with a BMI of 27–30 kg/m2 and a coexisting weight-related condition [39]. The study’s primary endpoint was the percentage change in body weight from baseline to 24 weeks of therapy. The secondary endpoints were the percentage change in body weight from baseline to 48 weeks and the presence of weight reduction in ≥5%, ≥10%, and ≥15%. 338 adults were enrolled in total. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was −7.2% in the 1 mg group, and up to −17.5% in the 12 mg group, as compared with −1.6% in the placebo group. Additionally, at 48 weeks, the same percentages were −8.7% in the 1 mg group, −24.2% in the 12 mg group, and −2.1% in the placebo group. At 48 weeks, a weight reduction of ≥5%, ≥10%, and ≥15% had occurred in 100%, 93%, and 83% of those who received 12 mg of retatrutide and 27%, 9%, and 2% of those who received placebo. The most common adverse effects were also gastrointestinal and dose-related and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Therefore, in adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.
In a similar manner, Rosenstock et al. [37] conducted a randomized, double-blind, phase 2 trial where adults aged 18–75 years with type 2 diabetes, HbA1c of 7.0–10.5%, and BMI of 25–50 kg/m2 were eligible for enrolment. Participants were treated with diet and exercise alone or with a stable dose of metformin for at least 3 months before screening. They were also randomly assigned to receive once-weekly injections of placebo, 1.5 mg dulaglutide, or retatrutide maintenance doses of 0.5 mg, 4 mg (starting dose 2 mg), 4 mg (no escalation), 8 mg (starting dose 2 mg), 8 mg (starting dose 4 mg), or 12 mg (starting dose 2 mg). The primary endpoint was a change in HbA1c from baseline to 24 weeks, and secondary endpoints included a change in HbA1c and body weight at 36 weeks. At 24 weeks, least-squares mean changes from baseline in HbA1c with retatrutide were –0.43% for the 0.5 mg group, –1.39% for the 4 mg escalation group, –1.30% for the 4 mg group, –1.99% for the 8 mg slow escalation group, –1.88% for the 8 mg fast escalation group, and –2.02% for the 12 mg escalation group, versus –0.01% for the placebo group and –1.41% for the 1.5 mg dulaglutide group. HbA1c reductions with retatrutide were significantly greater (p < 0.0001) than placebo in all but the 0.5 mg group and greater than 1.5 mg dulaglutide in the 8 mg slow escalation group (p = 0.0019) and 12 mg escalation group (p = 0.0002). Findings continued at 36 weeks. Bodyweight decreased dose-dependently with retatrutide at 36 weeks by up to 16.94% for the 12 mg escalation group, compared to 3.00% with placebo and 2.02% with 1.5 mg of dulaglutide. It was evident that retatrutide showed clinically meaningful improvements in glycaemic control and impressive reductions in body weight in type 2 diabetic patients while being relatively safe.
Another phase II trial by Sanyal et al. [44] attempted to show retatrutide’s effects on liver steatosis. 98 patients having ≥10% liver fat content (as defined by magnetic resonance imaging proton density fat fraction) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg dose) or placebo. In total, 76 participants managed to complete this substudy. The mean relative change from baseline in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg), and +0.3% (placebo). At 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg), and 0% (placebo) of participants. At 48 weeks, the mean relative change from baseline in liver fat was −51.3% (1 mg), −59.0% (4 mg), −81.7% (8 mg), −86.0% (12 mg), and −4.6% (placebo). Additionally, total liver fat content < 5% at 48 weeks was achieved with 8 mg (in 89% of participants) and 12 mg doses (in 93% of participants). Liver fat reduction was associated with weight loss, abdominal fat, and improved insulin sensitivity and lipid metabolism.

7. The Future—Phase III Trials
The promising results of the above trials led to the design of the first phase III trials for retatrutide—the TRIUMPH trials, where the efficacy and safety of retatrutide in participants who are obese or overweight will be evaluated. The first trial—TRIUMPH 1 is estimated to last until May 2026, and it aims to enrol 2300 patients [45].
The TRIUMPH-2 trial will evaluate the efficacy and safety of retatrutide in participants with T2DM who are obese or overweight, including a subset of participants who have obstructive sleep apnea (OSA). It aims to enrol 1000 patients, and it will last about 89 weeks with an expected due date of May 2026.
Another Phase III Trial—TRIUMPH 3 aims to investigate the per cent change from baseline in body weight in obese individuals with established cardiovascular disease (i.e., prior myocardial infarction). Participants must have excess weight, a history of heart attack, stroke, or presence of peripheral arterial disease, and also a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight in order to meet the eligibility criteria. Patients will be excluded (1) if they have had a heart attack, stroke, hospitalization for congestive heart failure or unstable angina within 90 days before screening, (2) if they have been taking any weight loss drugs, including over-the-counter medications, within 90 days before screening, (3) if they have had a change in body weight greater than 11 pounds within 90 days, (4) if they have or are planning a surgical treatment for excess weight, (5) if they have Type 1 Diabetes Mellitus, (6) if they have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) and (7) if they have had pancreatitis. The trial is expected to be completed in February 2026 with an enrolment goal of 1800 patients.
Finally, the TRIUMPH-4 study will assess the subset of obese or overweight participants with concomitant knee osteoarthritis, after being treated with retatrutide. It has an enrolment goal of 405 patients, and it is estimated to last until December 2025.
The planning and execution of additional phase III studies could offer in-depth insights into the critical factors influencing weight reduction. It is vital to understand that achieving weight loss is not always beneficial for health; in certain circumstances, it may lead to clinically significant declines in muscle and bone mass rather than a target reduction in fat. This phenomenon raises important questions about the quality and composition of weight loss, as retaining lean body mass is essential for maintaining overall strength, mobility, and metabolic health. Therefore, there is a need to design studies that not only focus on the percentage but also investigate the body composition changes that accompany weight loss [46,47,48,49].
It should be noted, however, that while retatrutide shows promise as a weight-loss therapy for adults, its use is not currently approved for children and adolescents. The safety and efficacy of retatrutide have not been established in pediatric populations. Current clinical trials have focused exclusively on adults, and there is a lack of data regarding its use in children and adolescents. Therefore, retatrutide is not indicated for individuals under 18 years of age. For children and adolescents, obesity prevention and management should prioritize non-pharmacological interventions. Lifestyle modifications, including a balanced diet and regular physical activity, are the cornerstone of pediatric obesity prevention. The U.S. Preventive Services Task Force recommends that clinicians screen for obesity in children and adolescents aged 6 years and older and offer or refer them to comprehensive, intensive behavioural interventions to promote improvements in weight status [50].

8. Conclusions
In conclusion, retatrutide appears to herald a significant advancement in the realm of pharmacotherapy for obesity and weight management (Figure 2). With its remarkable safety profile and noteworthy percentages of weight reduction, it undeniably generates considerable enthusiasm within the medical community. However, it is essential to emphasize that additional phase 3 clinical trials are crucial to further evaluate the drug’s safety and long-term effects.

Figure 2.

Open in a new tab
The present and future of Retatrutide.
Moreover, the financial implications of this groundbreaking medication cannot be ignored; despite its promising attributes, it may remain an inaccessible option for patients who cannot afford such treatments. Furthermore, studies assessing the quality of weight loss beyond simple BMI reduction are lacking, underscoring a significant area that warrants deeper research. This gap highlights the need for comprehensive studies that evaluate not only the effectiveness of weight loss but also its overall impact on patients’ health and well-being.

Interesting article. Are you guys on a trial study or are you ordering Retatrutide?

BadassBlues · Nov 21, 2025

Vince said:
Interesting article. Are you guys on a trial study or are you ordering Retatrutide?

We order it. I would love to be a part of a trial however... free stuff

KStrtguy · Dec 4, 2025

BadassBlues said:
We order it. I would love to be a part of a trial however... free stuff

What dose did you start at to experience that amount of weight loss in 2 weeks? Any other sides, such as low energy, brain fog, or insomnia? How are things now that you are farther out with the med?

BadassBlues · Dec 4, 2025

KStrtguy said:
What dose did you start at to experience that amount of weight loss in 2 weeks? Any other sides, such as low energy, brain fog, or insomnia? How are things now that you are farther out with the med?

I started with 1mg, which is a low dose. I have had unpleasant experiences with other GLP-1 drugs, so I wanted to start slow. After a week, I bumped it to 2 mg and have been on that dosage since. I'm going to go to 3 mg on my next injection.

I did feel the low energy side effects at first, but they have since cleared. No insomnia or brain fog.

The weight loss is amazing. I haven't weighed myself in a few weeks, but my pants were falling off of me, and I am now back in a size 34. Added benefits are a decrease in cravings and appetite. My wine consumption has decreased, which is a good thing

KStrtguy · Dec 4, 2025

BadassBlues said:
I started with 1mg, which is a low dose. I have had unpleasant experiences with other GLP-1 drugs, so I wanted to start slow. After a week, I bumped it to 2 mg and have been on that dosage since. I'm going to go to 3 mg on my next injection.

I did feel the low energy side effects at first, but they have since cleared. No insomnia or brain fog.

The weight loss is amazing. I haven't weighed myself in a few weeks, but my pants were falling off of me, and I am now back in a size 34. Added benefits are a decrease in cravings and appetite. My wine consumption has decreased, which is a good thing

Thanks for this info I appreciate it. I'm considering reta over tirz. Since I'm pushing 60 just looking for a little extra nutrition partitioning and fat burning. From what I've seen reta seems to be great at this. And from what I've read and it works synergistically with TRT and HGH or secretagouges. I appreciate it

t_spacemonkey · Dec 4, 2025

wife had amazing results, 60lb in 8 months or so. very few GI issues. the glucagon part of reta gives me some anxiety/insomnia unfortunately. at any dose. i need to lose like 20lb. i got here without glp's but a small appetite suppression is nice. not sure if i want to try tirz again, or just discipline and/or maybe a short sprint keto. i dont like keto but it works. i also don't gain any fat, so might use keto to get to goal and revert to my current diet

KStrtguy · Dec 4, 2025

t_spacemonkey said:
wife had amazing results, 60lb in 8 months or so. very few GI issues. the glucagon part of reta gives me some anxiety/insomnia unfortunately. at any dose. i need to lose like 20lb. i got here without glp's but a small appetite suppression is nice. not sure if i want to try tirz again, or just discipline and/or maybe a short sprint keto. i dont like keto but it works. i also don't gain any fat, so might use keto to get to goal and revert to my current diet

Yeah I think I saw some of your other posts on reta and the insomnia bit. I thought that was interesting I hadn't really seen a lot of that. Is that side effect dose dependent for you? Or is it regardless

t_spacemonkey · Dec 4, 2025

KStrtguy said:
Yeah I think I saw some of your other posts on reta and the insomnia bit. I thought that was interesting I hadn't really seen a lot of that. Is that side effect dose dependent for you? Or is it regardless

any dose, even at 200mcg. i think reta is really nice otherwise i would highly recommend. you can get it for like 1usd/1mg even you shop around

Seagal · Dec 5, 2025

Here it's more like 13E/mg. Anyone knows a reliable supplier within the EU?

MarcoFL · Dec 6, 2025

I just switched from Terzepitide 1.25mg every 5 days after being on for a year and now 0.5mg Retatrutide every other day and think my mind is more clear and increased energy. I am 13.3% body fat 63 in decent shape mainly want glucose control post meal. I like to be able to eats some carbs and have it back to base of 85 in 90 minutes. GLP's really help and all I hear about Reta is it is even better. More to come after a month or two in this.

Seagal · Dec 7, 2025

Retatrutide has a halflife of 5 days. Do you notice it? Would twice weekly be better?

BadassBlues · Dec 7, 2025

This stuff burns fat like Napalm... I have never lost weight this fast before. It's also quite a bit different from the other GLP-1 drugs regarding appetite control, it removes the cravings. It also changes your taste a bit. I am a wine enthusiast (read that as wino). Admittedly, I drink too much of it. This has cut that in half as I just don't crave it as much.

BadassBlues · Dec 7, 2025

Seagal said:
Retatrutide has a halflife of 5 days. Do you notice it? Would twice weekly be better?

Once a week is working for me, I haven't really noticed any kind of wearing off effects.

Trial	Population	Duration	Highest Reported Average Weight Loss
TRIUMPH-1	Obesity or overweight without diabetes	80 weeks	28.3% with 12 mg
TRIUMPH-1 extension	Starting BMI of at least 35	104 weeks	30.3% with 12 mg
TRIUMPH-4	Obesity or overweight with knee osteoarthritis	68 weeks	28.7% with 12 mg
TRIUMPH-2	Obesity or overweight with type 2 diabetes	80 weeks	20.8% with 12 mg
TRIUMPH-3	Severe obesity with established cardiovascular disease	80 weeks	22.6% with 12 mg

Target Dose	Trial Escalation
4 mg	2 mg, then 4 mg
9 mg	2 mg, 4 mg, 6 mg, then 9 mg
12 mg	2 mg, 4 mg, 6 mg, 9 mg, then 12 mg

Retatrutide: Weight Loss, Dosing, Side Effects 2026

Share this page

What is retatrutide and how does it work?​

How much weight loss did retatrutide produce in Phase 3 trials?​

Why does the statistical method used in TRIUMPH-1 matter?​

What health effects occurred beyond retatrutide weight loss?​

What happened to liver fat with retatrutide?​

Does retatrutide reduce heart attacks or strokes?​

What happens to muscle and lean mass during retatrutide treatment?​

Does TRT prevent muscle loss during retatrutide treatment?​

Which retatrutide side effects appear most often?​

What is dysesthesia and why does retatrutide cause concern about it?​

What retatrutide dosing schedules were used in Phase 3 trials?​

Is the highest retatrutide dose always the best dose?​

Is retatrutide FDA approved or legally compounded in the United States?​

What are ExcelMale members reporting about retatrutide?​

What questions do readers ask most about retatrutide?

Is retatrutide a GLP-3 drug?

How much weight did people lose with retatrutide?

Does retatrutide preserve muscle?

Does TRT prevent muscle loss from retatrutide?

Is retatrutide better than tirzepatide or semaglutide?

What retatrutide doses were studied?

Is the Phase 3 dosing schedule an approved retatrutide protocol?

Is compounded retatrutide legal in the United States?

When is retatrutide expected to reach the FDA?

Which ExcelMale discussions add useful real-world context?​

What matters most as retatrutide moves toward FDA review?​

Which sources support this retatrutide guide?​

Who wrote this article?​

What is ExcelMale?​

Retatrutide—A Game Changer in Obesity Pharmacotherapy​

Abstract​

1. Introduction​

2. Materials and Methods​

3. Targeted Molecules​

3.1. Glucagon-like Peptide (GLP-1)​

3.2. Glucose-Dependent Insulinotropic Polypeptide (GIP)​

3.3. Glucagon​

4. General Aspects of Retatrutide​

Molecular Structure—Pharmacology​

Figure 1.​

5. Insights from Animal Studies​

Table 1.​

6. Insights from Human Studies​

6.1. Phase I Trials​

6.2. Phase II Trials​

7. The Future—Phase III Trials​

8. Conclusions​

Figure 2.​

ExcelMale Newsletter Signup

Stay Informed with Our Newsletter

Similar threads

Sponsors

Share this page

Online statistics

Beyond Testosterone Podcast

What is retatrutide and how does it work?

How much weight loss did retatrutide produce in Phase 3 trials?

Why does the statistical method used in TRIUMPH-1 matter?

What health effects occurred beyond retatrutide weight loss?

What happened to liver fat with retatrutide?

Does retatrutide reduce heart attacks or strokes?

What happens to muscle and lean mass during retatrutide treatment?

Does TRT prevent muscle loss during retatrutide treatment?

Which retatrutide side effects appear most often?

What is dysesthesia and why does retatrutide cause concern about it?

What retatrutide dosing schedules were used in Phase 3 trials?

Is the highest retatrutide dose always the best dose?

Is retatrutide FDA approved or legally compounded in the United States?

What are ExcelMale members reporting about retatrutide?

Which ExcelMale discussions add useful real-world context?

What matters most as retatrutide moves toward FDA review?

Which sources support this retatrutide guide?

Who wrote this article?

What is ExcelMale?

Retatrutide—A Game Changer in Obesity Pharmacotherapy

Abstract

1. Introduction

2. Materials and Methods

3. Targeted Molecules

3.1. Glucagon-like Peptide (GLP-1)

3.2. Glucose-Dependent Insulinotropic Polypeptide (GIP)

3.3. Glucagon

4. General Aspects of Retatrutide

Molecular Structure—Pharmacology

Figure 1.

5. Insights from Animal Studies

Table 1.

6. Insights from Human Studies

6.1. Phase I Trials

6.2. Phase II Trials

7. The Future—Phase III Trials

8. Conclusions

Figure 2.